A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Recruiting

Phase 1

Phase 2

IDE849A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Sponsor:

IDEAYA Biosciences

Code:

NCT07174583

Conditions

Small-cell Lung Cancer

Neuroendocrine Carcinomas

Solid Tumor Show to Express DLL3

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IDE849

durvalumab

IDE161

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-14. This information was provided to ClinicalTrials.gov by IDEAYA Biosciences on 2026-01-23.